Disappointingly, targeting HER2 with traditional anti-HER2 agents which were proved to be effective in breast and gastric cancer has failed in other tumor types, indicating the histological and biological diversity of HER2 alternations in distinct malignancies (5). The gene discussed is ERBB2; the disease is neoplasm.